NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos is presenting two scientific posters, based on collaborations with Drs. Kenneth Tew and Danyelle Townsend of the Medical University of South Carolina, Charleston, SC, and Drs. Alberto Montero and C. Marcela Diaz-Montero of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL at the ongoing AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. These presentations report findings in animal and cellular tumor model systems that add to the understanding of the pharmacological actions of NOV-002 and how these may relate to its clinical profile in oncology patients. An abstract of each poster presentation has been published in the conference proceedings. NOV-002 is in a pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, which is expected to conclude in early 2010. NOV-002 has also demonstrated positive results in Phase 2 trials for other cancer indications.
